These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 16225469)

  • 1. Review article: the metabolic syndrome and non-alcoholic fatty liver disease.
    Loria P; Lonardo A; Carulli L; Verrone AM; Ricchi M; Lombardini S; Rudilosso A; Ballestri S; Carulli N
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():31-6. PubMed ID: 16225469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-alcoholic steatohepatitis and metabolic syndrome.
    Machado M; Cortez-Pinto H
    Curr Opin Clin Nutr Metab Care; 2006 Sep; 9(5):637-42. PubMed ID: 16912563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome.
    Tarantino G; Saldalamacchia G; Conca P; Arena A
    J Gastroenterol Hepatol; 2007 Mar; 22(3):293-303. PubMed ID: 17295757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertension and fatty liver: guilty by association?
    Brookes MJ; Cooper BT
    J Hum Hypertens; 2007 Apr; 21(4):264-70. PubMed ID: 17273155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
    Fan JG; Saibara T; Chitturi S; Kim BI; Sung JJ; Chutaputti A;
    J Gastroenterol Hepatol; 2007 Jun; 22(6):794-800. PubMed ID: 17498218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: Drug therapy for non-alcoholic fatty liver disease.
    Comar KM; Sterling RK
    Aliment Pharmacol Ther; 2006 Jan; 23(2):207-15. PubMed ID: 16393299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: steatosis, the metabolic syndrome and cancer.
    Bugianesi E
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():40-3. PubMed ID: 16225471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response.
    Younossi ZM; McCullough AJ
    Liver Int; 2009 Mar; 29 Suppl 2():3-12. PubMed ID: 19187068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent concepts in non-alcoholic fatty liver disease.
    Adams LA; Angulo P
    Diabet Med; 2005 Sep; 22(9):1129-33. PubMed ID: 16108837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease pathogenesis: the present and the future.
    Petta S; Muratore C; Craxì A
    Dig Liver Dis; 2009 Sep; 41(9):615-25. PubMed ID: 19223251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease: defining a common problem.
    Gasbarrini G; Vero V; Miele L; Forgione A; Hernandez AP; Greco AV; Gasbarrini A; Grieco A
    Eur Rev Med Pharmacol Sci; 2005; 9(5):253-9. PubMed ID: 16231586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications.
    Fan JG
    J Dig Dis; 2008 May; 9(2):63-7. PubMed ID: 18419637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic syndrome and NASH.
    Marchesini G; Marzocchi R
    Clin Liver Dis; 2007 Feb; 11(1):105-17, ix. PubMed ID: 17544974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma.
    Takamatsu S; Noguchi N; Kudoh A; Nakamura N; Kawamura T; Teramoto K; Igari T; Arii S
    Hepatogastroenterology; 2008; 55(82-83):609-14. PubMed ID: 18613418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management.
    Byrne CD
    Diabet Med; 2012 Sep; 29(9):1098-107. PubMed ID: 22672330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question.
    Loria P; Lonardo A; Bellentani S; Day CP; Marchesini G; Carulli N
    Nutr Metab Cardiovasc Dis; 2007 Nov; 17(9):684-98. PubMed ID: 17560098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease and hepatitis C infection.
    Bondini S; Younossi ZM
    Minerva Gastroenterol Dietol; 2006 Jun; 52(2):135-43. PubMed ID: 16557185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications.
    Tsochatzis EA; Manolakopoulos S; Papatheodoridis GV; Archimandritis AJ
    Scand J Gastroenterol; 2009; 44(1):6-14. PubMed ID: 18661429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.